Efficacy and safety of anti-TNF agents in the Lombardy rheumatoid arthritis network (LORHEN)

Efficacy and safety of anti-TNF agents in the Lombardy rheumatoid arthritis network (LORHEN)

Clinical trials have shown that anti-tumour necrosis factor (TNF)-α drugs are effective in patients with rheumatoid arthritis (RA) refractory to disease- modifying antirheumatic drugs (DMARDs) (1-4). At about the same time as the European approval of the third anti-TNFα agent (adalimumab) for treati...

Full description

Bibliographic Details
Main Authors: R. Caporali, M. Filippini, R. Gorla, E.G. Favalli, A. Marchesoni, M. Antivalle, P. Sarzi- Puttini, F. Bobbio-Pallavicini, C. Montecucco, F. Atzeni
Format: Article
Language:English
Published: PAGEPress Publications 2011-09-01
Series:Reumatismo
Online Access:http://www.reumatismo.org/index.php/reuma/article/view/403
id doaj-a3e6e4291560442c8293fdb98392bc26
record_format Article
spelling doaj-a3e6e4291560442c8293fdb98392bc262020-11-24T23:27:25ZengPAGEPress PublicationsReumatismo0048-74492240-26832011-09-0160429029510.4081/reumatismo.2008.290Efficacy and safety of anti-TNF agents in the Lombardy rheumatoid arthritis network (LORHEN)R. CaporaliM. FilippiniR. GorlaE.G. FavalliA. MarchesoniM. AntivalleP. Sarzi- PuttiniF. Bobbio-PallaviciniC. MontecuccoF. AtzeniClinical trials have shown that anti-tumour necrosis factor (TNF)-α drugs are effective in patients with rheumatoid arthritis (RA) refractory to disease- modifying antirheumatic drugs (DMARDs) (1-4). At about the same time as the European approval of the third anti-TNFα agent (adalimumab) for treating RA patients, the Italian Society of Rheumatology (Società Italiana di Reumatologia [SIR]) started a database for the registration and active follow-up of RA patients treated with biological response modifiers, which contains all of the demographic and clinical parameters, as well as the therapeutic data, usually needed to follow RA patients...http://www.reumatismo.org/index.php/reuma/article/view/403
collection DOAJ
language English
format Article
sources DOAJ
author R. Caporali
M. Filippini
R. Gorla
E.G. Favalli
A. Marchesoni
M. Antivalle
P. Sarzi- Puttini
F. Bobbio-Pallavicini
C. Montecucco
F. Atzeni
spellingShingle R. Caporali
M. Filippini
R. Gorla
E.G. Favalli
A. Marchesoni
M. Antivalle
P. Sarzi- Puttini
F. Bobbio-Pallavicini
C. Montecucco
F. Atzeni
Efficacy and safety of anti-TNF agents in the Lombardy rheumatoid arthritis network (LORHEN)
Reumatismo
author_facet R. Caporali
M. Filippini
R. Gorla
E.G. Favalli
A. Marchesoni
M. Antivalle
P. Sarzi- Puttini
F. Bobbio-Pallavicini
C. Montecucco
F. Atzeni
author_sort R. Caporali
title Efficacy and safety of anti-TNF agents in the Lombardy rheumatoid arthritis network (LORHEN)
title_short Efficacy and safety of anti-TNF agents in the Lombardy rheumatoid arthritis network (LORHEN)
title_full Efficacy and safety of anti-TNF agents in the Lombardy rheumatoid arthritis network (LORHEN)
title_fullStr Efficacy and safety of anti-TNF agents in the Lombardy rheumatoid arthritis network (LORHEN)
title_full_unstemmed Efficacy and safety of anti-TNF agents in the Lombardy rheumatoid arthritis network (LORHEN)
title_sort efficacy and safety of anti-tnf agents in the lombardy rheumatoid arthritis network (lorhen)
publisher PAGEPress Publications
series Reumatismo
issn 0048-7449
2240-2683
publishDate 2011-09-01
description Clinical trials have shown that anti-tumour necrosis factor (TNF)-α drugs are effective in patients with rheumatoid arthritis (RA) refractory to disease- modifying antirheumatic drugs (DMARDs) (1-4). At about the same time as the European approval of the third anti-TNFα agent (adalimumab) for treating RA patients, the Italian Society of Rheumatology (Società Italiana di Reumatologia [SIR]) started a database for the registration and active follow-up of RA patients treated with biological response modifiers, which contains all of the demographic and clinical parameters, as well as the therapeutic data, usually needed to follow RA patients...
url http://www.reumatismo.org/index.php/reuma/article/view/403
work_keys_str_mv AT rcaporali efficacyandsafetyofantitnfagentsinthelombardyrheumatoidarthritisnetworklorhen
AT mfilippini efficacyandsafetyofantitnfagentsinthelombardyrheumatoidarthritisnetworklorhen
AT rgorla efficacyandsafetyofantitnfagentsinthelombardyrheumatoidarthritisnetworklorhen
AT egfavalli efficacyandsafetyofantitnfagentsinthelombardyrheumatoidarthritisnetworklorhen
AT amarchesoni efficacyandsafetyofantitnfagentsinthelombardyrheumatoidarthritisnetworklorhen
AT mantivalle efficacyandsafetyofantitnfagentsinthelombardyrheumatoidarthritisnetworklorhen
AT psarziputtini efficacyandsafetyofantitnfagentsinthelombardyrheumatoidarthritisnetworklorhen
AT fbobbiopallavicini efficacyandsafetyofantitnfagentsinthelombardyrheumatoidarthritisnetworklorhen
AT cmontecucco efficacyandsafetyofantitnfagentsinthelombardyrheumatoidarthritisnetworklorhen
AT fatzeni efficacyandsafetyofantitnfagentsinthelombardyrheumatoidarthritisnetworklorhen
_version_ 1725551982136000512

Similar Items